Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the diagnosed breast cancer population in China will increase substantially. According to the new Emerging Markets report entitled Breast Cancer in China, a rapidly aging population will be a key driving force behind an increase of almost 25% in the breast cancer diagnosed incident population between 2006 and 2011 in China, as average life expectancy rises and deaths from infectious diseases fall. Additionally, sustained migration from rural to urban China during recent decades has exposed more individuals to risk factors for breast cancer that are associated with urbanization.
"The diagnosed incident breast cancer population in China will increasingly be distributed toward urban areas, where a growing number of residents continue to adopt nutritional patterns and sedentary lifestyles typical of Western countries," said Ramya Kollipara, Ph.D., analyst at Decision Resources. "The burden of disease will grow disproportionately in cities as a result of urbanization."
The report also finds that Roche's Herceptin will experience higher penetration in the treatment-eligible population in China, and sales of this agent will increase rapidly between 2006 and 2011. Clinicians are becoming more familiar with this agent, which has shown better efficacy and toxicity profiles in Chinese patients than the market-leading small molecules.
About Emerging Markets - China
Emerging Markets - China is the first and only syndicated report series focusing on a high-growth emerging market with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:
-- More accurately assess their commercial opportunity for Western brands in key pharmaceutical markets of China - Beijing, Shanghai, Guangzhou - and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou, and Jinan. -- Understand the physician treatment patterns and drivers of choice in key first- and second-tier cities based on primary research. -- Gain a clear perspective of the Chinese five-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and Chinese-based companies. About Decision Resources
Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563
Web site: http://www.decisionresources.com/